Genetics of antipsychotic drug outcome and implications for the clinician: into the limelight
Authors:
- Amtul H. ChangasiACAmtul H. Changasi
- Tahireh A. ShamsTSTahireh A. Shams
- Jennie G. PougetJPJennie G. Pouget
Open Access
- 1 January 2014
- journal article
- Published by Taylor & Francis in Translational Developmental Psychiatry
- Vol. 2 (1)
Abstract
Genetics of antipsychotic drug outcome and implications for the clinician: into the limelightKeywords
This publication has 19 references indexed in Scilit:
- Towards the implementation ofCYP2D6andCYP2C19genotypes in clinical practice: Update and report from a pharmacogenetic service clinicInternational Review of Psychiatry, 2013
- Complexities ofCYP2D6gene analysis and interpretationInternational Review of Psychiatry, 2013
- Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapyInternational Review of Psychiatry, 2013
- The AmpliChip ® CYP450 Test and Response to Treatment in Schizophrenia and Obsessive Compulsive Disorder: A Pilot Study and Focus on Cases with Abnormal CYP2D6 Drug MetabolismGenetic Testing and Molecular Biomarkers, 2012
- A review of the use of clozapine levels to guide treatment and determine cause of deathAustralian & New Zealand Journal of Psychiatry, 2012
- The Pharmacogenetics of Symptom Response to Antipsychotic DrugsPsychiatry Investigation, 2012
- Genetic variation in CYP3A43 explains racial difference in olanzapine clearanceMolecular Psychiatry, 2011
- Psychiatric Pharmacogenomics2010
- CYTOCHROME P-450 3A4: Regulation and Role in Drug MetabolismAnnual Review of Pharmacology and Toxicology, 1999
- A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotypePharmacogenetics, 1995